Chairman and CEO
Eugene Williams is a former SVP at Genzyme, with senior roles integrating commercialization, drug development, and deal making. He is also an entrepreneur, as the founder and director of Adheris, which became the largest company in the patient adherence area. He was previously a strategy consultant at Bain and Corporate Decisions Inc. (a Bain Spin off, now part of Oliver Wyman), where he was co-Head of Healthcare and spent extensive time on speeding and improving the drug development process and on commercialization strategies. Mr. Williams was most recently the CEO of Dart Therapeutics, an Orphan Disease drug development company. Mr. Williams holds a BA from Harvard University and an MBA from Harvard Business School.
Dr. Neil Cashman
Chief Scientific Officer and Co-founder
Dr. Cashman is a physician and scientist focused on neurodegenerative diseases. His first academic posting was at Montreal Neurological Institute and Hospital of McGill University. From 1998 to 2005, he was the Diener Professor of Neurodegenerative Diseases at the University of Toronto. In 2005, Professor Cashman moved to the University of British Columbia, where he holds the Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases and serves as the Director of the UBC ALS Centre. He has procured over $50 million in research grant funding from the CIHR, CRC, NCE, NIH, and various corporations for his work involving protein misfolding and prion technologies. He was awarded the Jonas Salk Prize for biomedical research in 2000 and was elected a Fellow of the Canadian Academy of Health Sciences in 2008. He is recognized worldwide as one of the leading research scientists pioneering the emerging fields of prion biology and protein misfolding diseases, in particular Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).
Prior to his retirement, Dr. Gregory served as Executive Vice President and Chief Scientific Officer of ImmunoGen, Inc., a biotechnology company, from 2015 until August 2019. In this capacity he provided leadership and direction to the Research organization and was responsible for the generation of development candidates based upon ImmunoGen’s Antibody Drug Conjugate technology. Prior to ImmunoGen, Richard held a variety of roles at Genzyme and Sanofi-Genzyme, including Vice President for Gene Therapy, Head of Corporate Research and Head of R&D for the Sanofi/Genzyme R&D Center. Rich received his BSc in Biochemistry from Virginia Tech, his PhD in Biochemistry from the University of Massachusetts, and did his post-doctoral training in cancer genetics at the Worcester Foundation for Experimental Biology. He is the co-author of over 60 peer-reviewed publications and 23 issued U.S. patents in the area of biotechnology. Richard is a Fellow of the American Institute for Medical and Biological Engineering.
Senior partner at Kirwin LLP, has been advising and representing businesses in a range of industries and sizes from local to multinational for over 30 years. He obtained his BA in Economics (First Class Standing) from the University of Alberta in 1978 followed by his JD from the University of Toronto, Faculty of law in 1982. He practiced initially with the Canadian Federal Department of Justice from 1982 to 1986 then founded the predecessor to Kirwin LLP where he currently practices in Edmonton, Alberta.
Josh Mandel-Brehm is President & Chief Executive Officer of CAMP4 Therapeutics and holds a dual appointment as entrepreneur partner with Polaris Partners. He is also a co-founder and board member for Vico Therapeutics, an oligonucleotide-based RNA modulating Company focused on developing therapeutics for patients suffering from rare CNS disorders.
Mr. Mandel-Brehm previously held key business development and operations leadership roles at leading biotech companies. Most recently he served as part of the Business Development group at Biogen, where he led multiple strategic activities and corresponding transactions, which included expanding Biogen’s non-malignant hematology franchise, overseeing seminal investments to enter the ophthalmology field and advancing Biogen’s gene therapy strategy. Prior to Biogen, Mr. Mandel-Brehm held several roles of increasing responsibility at Genzyme as part of the business development group for the company’s rare disease business unit.
Mr. Mandel-Brehm earned a BA in Biology from Washington University in St. Louis and holds an MBA from the University of Michigan.
Maggie has almost 30 years of experience providing intellectual property advice to the biotechnology and pharmaceutical industries. She holds a B.A. in Biology from University of California, a Ph.D. in Molecular Biology and Virology from Cornell University Graduate School of Medical Sciences and a J.D. summa cum laude from New York Law School. After spending 8 years at the boutique IP firm of Fish & Neave in New York, Maggie spent 14 years at Genzyme, where she ultimately became Sr. Vice President and Chief Patent Counsel. In that role, she was responsible for providing strategic guidance and IP advice for major commercial and research transactions as well as for developing and implementing strategies to procure, license, defend and enforce Genzyme’s worldwide intellectual property. Upon Genzyme’s acquisition by Sanofi, Maggie became Vice President and Chief Patent Counsel at Sanofi Pasteur, where she was responsible for leading IP attorneys and agents in the U.S., Canada, France and India. In 2014, Maggie became an independent IP consultant, providing strategic advice related to IP portfolio development, commercial transactions and potential and ongoing patent and trade secret disputes.
Neil K. Warma
Neil K. Warma, MBA, was appointed to the Board of Directors in May 2021. Neil Warma has been a successful healthcare entrepreneur for over 25 years having founded, managed and advised numerous biotech and pharmaceutical companies across the globe. Currently, Mr. Warma is the General Manager of I-Mab Biopharma U.S., (Nasdaq:IMAB) a publicly traded global biopharmaceutical company with offices and research labs in China (Shanghai, Beijing) and the U.S. (San Diego, Gaithersburg) that focuses on developing and commercializing novel immuno oncology drugs. Previously, as President and CEO of Opexa Therapeutics (Nasdaq:OPXA), a publicly traded biopharmaceutical company, Mr. Warma led the turnaround and rebuilding of the company’s cell therapy platform and oversaw its advance through clinical development in autoimmune and orphan diseases, expansion into China and its eventual merger with Acer Therapeutics (Nasdaq:ACER). Prior to Opexa, he was CEO of Viron Therapeutics, a private biotechnology company developing novel protein-based therapeutics for cardiovascular disease and transplantation.
William W. Wyman began his career at the management consulting firm Booz Allen and Hamilton. After working for the firm in New York, Duesseldorf Germany, Athens Greece, and Dallas Texas, he returned to New York to become the President of the Management Consulting Group, a member of the executive committee, and a member of the Board of Directors. Subsequently, Mr. Wyman co-founded the management consulting firm, Oliver Wyman & Co. Now part of Marsh & McLennan, the firm employs 3,700 professionals in 26 countries.
Mr Wyman has served as director to more than eighteen public and private companies, mostly smaller companies in the technology and finance sectors. He also has served as an advisor to several private equity partnerships.
Mr. Wyman received his BA from Colgate University, and his MBA from the Harvard Business School. He also served in the U.S. Navy for four years. He resides in Hanover, NH.